Display options
Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803.
Copy Download .nbib Format: NLM
Share it on

Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Adam N Pelletier, Rafick P Sekaly, Jeffrey A Tomalka

Affiliations

  1. RPM Bioinfo Solutions, Blainville, Quebec, Canada.
  2. Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  3. Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: [email protected].

PMID: 34902803 DOI: 10.1016/j.coviro.2021.11.012

Abstract

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls into question how effective current SARS-CoV-2 vaccines will be moving forward. Improving on vaccine platforms represents an opportunity to stay ahead of SARS-CoV-2 and keep the human population protected. Many researchers focus on modifying delivery platforms or altering the antigen(s) presented to improve the efficacy of the vaccines. Identifying mechanisms of natural immunity that result in the control of infection and prevent poor clinical outcomes provides an alternative approach to the development of efficacious vaccines. Early and current evidence shows that SARS-CoV-2 infection is marked by potent lung inflammation and relatively diminished antiviral signaling which leads to impaired immune recognition and viral clearance, essentially making SARS-CoV-2 'too hot to handle'.

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Publication Types